Genmab: submits application to market myeloma drug in Japan
(CercleFinance.com) - Denmark's Genmab said it has submitted an application for marketing its multiple myeloma drug Darzalex in Japan.
Genmab and its partner Janssen have submitted a supplemental new drug application to the Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Genmab said that the application will receive a priority review.
The submission of the application triggers a milestone payment of 2 million dollars from Janssen, it added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Genmab and its partner Janssen have submitted a supplemental new drug application to the Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Genmab said that the application will receive a priority review.
The submission of the application triggers a milestone payment of 2 million dollars from Janssen, it added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.